Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


The ESMO Gynaecological Cancers Virtual Congress 2021 programme is now online!

Access the online programme

The “ESMO Gynaecological Cancers Congress” will provide insights in the diagnosis, biology and therapy of gynaecological malignancies, focusing on ovarian cancer in 2021. Specifically, the congress will include educational and scientific sessions covering:

  • Controversy topics, such as the role of immunotherapy in ovarian cancer
  • Discussion of therapeutic strategies highlighted by clinical case presentations
  • Educational roundtables on the state of the art management of patients throughout the disease course
  • Best of abstract sessions for recapitulation and in-depth critical review of the scientific breakthroughs related to ovarian cancer during the year
  • Keynote lecture

Learning objectives

  • To provide updates on state of the art multidisciplinary management of patients with ovarian cancer
  • To highlight the latest scientific advances in profiling, prognostication and management of patients with ovarian cancer
  • To summarize established and emerging knowledge on biomarkers applicable for prognosis and treatment selection in patients with ovarian cancer
  • To assist young oncologists with expert advice on professional development


ESMO-MORA: The ESMO Gynaecological Cancers Virtual Programme has been accredited with 8 cat.1 ESMO-MORA points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.


All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).

The experts invited by ESMO as Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.

The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.


The Congress webcasts will include all the sessions of the official programme, where speaker permission is granted, and will be available on the page dedicated to meeting resources on this website and OncologyPRO for ESMO members.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.